Observational studyInternational journal of molecular sciences2023

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).

Marco Stellato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.